Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2019
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1Cecilia Roux, Soode Moghadas Jafari, Rahul Shinde, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2014
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathwayChiara Gorrini, Bevan P Gang, Christian Bassi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
British Journal of Cancer|July 16, 2019
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialZachary W Veitch, David W Cescon, Trisha Denny, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 2020
Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and RadiationDana Keilty, Shirin Nezafat Namini, Monali Swain, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2018
Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibitionMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosisDavid W Cescon, Penelope A Bradbury, Kofi Asomaning, et al.
NPJ Breast Cancer|December 15, 2025
The role of circulating tumor cell-associated genes in the progression of estrogen receptor-positive breast cancerMartin Rotbauer, Melanie Dawe, Kevin C J Nixon, et al.
Nature Communications|June 4, 2026
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapyMitchell J Elliott, Jesús Fuentes-Antrás, Sasha C Main, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2019
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1Cecilia Roux, Soode Moghadas Jafari, Rahul Shinde, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2014
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathwayChiara Gorrini, Bevan P Gang, Christian Bassi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
British Journal of Cancer|July 16, 2019
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialZachary W Veitch, David W Cescon, Trisha Denny, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 2020
Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and RadiationDana Keilty, Shirin Nezafat Namini, Monali Swain, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2018
Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibitionMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosisDavid W Cescon, Penelope A Bradbury, Kofi Asomaning, et al.
NPJ Breast Cancer|December 15, 2025
The role of circulating tumor cell-associated genes in the progression of estrogen receptor-positive breast cancerMartin Rotbauer, Melanie Dawe, Kevin C J Nixon, et al.
Nature Communications|June 4, 2026
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapyMitchell J Elliott, Jesús Fuentes-Antrás, Sasha C Main, et al.
Pageof 14